FDA Generic Drug Approval Standards and Quality Assurance

FDA regulations for generic drugs require the same safety, efficacy, and formulation as branded drugs, forming the core of market trust. TEVA, a global leader in generic pharmaceuticals (Teva Pharmaceutical Industries Ltd., TEVA), demonstrated to regulatory authorities that its generic drug is identical to the original in terms of composition and drug release rate, thereby securing bioequivalence. Through this, TEVA obtained final approval for the abbreviated new drug application (ANDA) on May 21, 2021, following the generic drug approval process of therapeutic equivalence verification. This indicates the presence of a rigorous quality management process to overcome regulatory barriers.

Patent Expiry of Blockbuster Therapy Revlimid and Market Structure Changes

The target of this generic launch, Revlimid (active ingredient lenalidomide), is a representative immunomodulatory drug that has revolutionized the treatment of multiple myeloma. This drug works by targeting the Cereblon (CRBN) E3 ligase molecule to promote the degradation of abnormal proteins. The original developer, Bristol Myers Squibb (BMY), reported global sales of USD 12.82 billion (USD 12.82B) from Revlimid alone in 2021. TEVA's generic launch marks the first step in breaking the original drug's monopoly, which was valued in the tens of billions of dollars annually.

Patent Settlement and Volume-Limited Strategy Facilitated Gradual Market Entry

TEVA's generic lenalidomide began to be officially supplied to U.S. pharmacies on March 7, 2022. This was made possible by a patent settlement reached following a patent infringement lawsuit with the original patent holder, Celgene (now BMS). Under this settlement, TEVA secured a leading supply position with a volume-limited license, restricting its market share until January 31, 2026. After this date, when the share restrictions are fully lifted, unrestricted sales will become possible, initiating a true price competition regime.

Ripple Effects of Generic Market Expansion on Public Health and the Biopharma Ecosystem

The supply of affordable generics in the U.S. multiple myeloma treatment market has significant public health and economic implications by reducing patients' direct medication costs. It also contributes to the financial sustainability of national healthcare systems and influences the prescription patterns of standard of care (SOC) within the same indication among competitors. Particularly, it will impact the pricing strategies of combination therapy pipelines such as Daratumumab and Pomalidomide. Original developers will reallocate resources toward next-generation biopharmaceuticals or novel modalities in response to patent expiry.